European Respiratory Journal

Papers
(The H4-Index of European Respiratory Journal is 87. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis1993
Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study924
ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19580
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge546
Pathogenesis of COVID-19 from a cell biology perspective541
Cardiovascular comorbidity and its impact on patients with COVID-19453
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension411
A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis355
The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19337
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline327
Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset311
ERS/ATS technical standard on interpretive strategies for routine lung function tests296
Association between age and clinical characteristics and outcomes of COVID-19277
Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial272
No association of COVID-19 transmission with temperature or UV radiation in Chinese cities271
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study267
Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?265
ERS statement on chronic thromboembolic pulmonary hypertension263
Pulmonary embolism in patients with COVID-19 pneumonia263
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients249
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial249
COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society- and American Thoracic Society-coordinated international task force244
ERS clinical practice guidelines on treatment of sarcoidosis238
COVID-19 and pneumothorax: a multicentre retrospective case series219
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19212
COVID-19 and COPD210
Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China209
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes207
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases196
Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation195
Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective195
High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion182
Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia182
Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study181
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19178
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary173
Universal use of face masks for success against COVID-19: evidence and implications for prevention policies170
Trends in worldwide asthma prevalence163
Pathogenesis of COVID-19-induced ARDS: implications for an ageing population158
Will children reveal their secret? The coronavirus dilemma152
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome148
The potential impact of COVID-19-related disruption on tuberculosis burden145
Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study143
The impact of COVID-19 on patients with asthma142
Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication140
The natural history of progressive fibrosing interstitial lung diseases140
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline139
Patient-reported outcome measures after COVID-19: a prospective cohort study137
Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry136
Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection136
Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China135
COVID-19 and smoking: is nicotine the hidden link?132
Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors132
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma131
Thrombosis and COVID-19 pneumonia: the clot thickens!129
Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study126
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update126
Mepolizumab effectiveness and identification of super-responders in severe asthma122
Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue121
Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation119
Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers117
Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life115
Understanding the renin–angiotensin–aldosterone–SARS-CoV axis: a comprehensive review114
Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study110
Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study107
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension107
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection107
ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure106
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase105
Current smoking is not associated with COVID-19104
Methotrexate and rheumatoid arthritis associated interstitial lung disease104
Endothelial cells in the pathogenesis of pulmonary arterial hypertension101
Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swabversusprofessional-collected nasopharyngeal swab101
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis101
Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital101
Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry100
European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years98
E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies98
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)95
Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis95
Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study92
Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial92
Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics90
European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis90
Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences90
Diffusion Capacity Abnormalities for Carbon Monoxide in Patients with COVID-19 At Three-Month Follow-up90
Novel coronavirus infection in newborn babies aged <28 days in China89
0.038096189498901